# eFFECTOR Therapeutics Inc. (EFTR)

Source: https://www.quantisnow.com/company/EFTR
Generated: 2026-11-19T15:50:24.463Z

- Ticker: EFTR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: effector.com

## About

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

## Latest EFTR news and filings

- 2024-08-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-effector-therapeutics-inc-5639376)
- 2024-08-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-effector-therapeutics-inc-5639371)
- 2024-08-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-effector-therapeutics-inc-5639368)
- 2024-08-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-effector-therapeutics-inc-5639358)
- 2024-07-30 20:19 UTC [SEC Form 15-12G filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-effector-therapeutics-inc-5633397)
- 2024-07-30 20:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-effector-therapeutics-inc-5633370)
- 2024-07-30 20:13 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-effector-therapeutics-inc-5633263)
- 2024-07-30 20:11 UTC [SEC Form POS AM filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-effector-therapeutics-inc-5633229)
- 2024-07-30 20:07 UTC [SEC Form POS AM filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-effector-therapeutics-inc-5633161)
- 2024-07-30 20:05 UTC [SEC Form POS AM filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-effector-therapeutics-inc-5633128)
- 2024-07-30 20:01 UTC [SEC Form POS AM filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-effector-therapeutics-inc-5633009)
- 2024-07-19 13:22 UTC [SEC Form 25-NSE filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-effector-therapeutics-inc-5617184)
- 2024-06-26 10:05 UTC [Market Chatter] [eFFECTOR Therapeutics Declared in Default on $75M Oxford Finance Loan](https://www.quantisnow.com/insight/effector-therapeutics-declared-in-default-on-75m-oxford-finance-loan-5577337)
- 2024-06-26 00:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-effector-therapeutics-inc-5577283)
- 2024-06-25 21:16 UTC [SEC Form 8-K] [SEC Form 8-K filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-effector-therapeutics-inc-5576913)
- 2024-06-24 17:06 UTC [Market Insight] [Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher](https://www.quantisnow.com/insight/dow-jumps-300-points-alimera-sciences-shares-spike-higher-5573275)
- 2024-06-24 15:26 UTC [Market Insight] [Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%](https://www.quantisnow.com/insight/why-effector-therapeutics-eftr-shares-are-down-over-70-5573070)
- 2024-06-24 11:41 UTC [Market Chatter] [EFFECTOR Therapeutics shares are trading lower after the company announced that it has terminated its employees and will wind down its operations. Also, the company announced it plans to voluntarily request a delisting of its securities on the Nasdaq.](https://www.quantisnow.com/insight/effector-therapeutics-shares-are-trading-lower-after-the-company-announced-5572372)
- 2024-06-24 11:06 UTC [SEC Form 8-K] [SEC Form 8-K filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-effector-therapeutics-inc-5572268)
- 2024-06-24 11:01 UTC [Market Chatter] [eFFECTOR Therapeutics To Wind Down Operations And Seek Potential Strategic Alternatives, Expects To Delist From Nasdaq](https://www.quantisnow.com/insight/effector-therapeutics-to-wind-down-operations-and-seek-potential-strategic-5572247)
- 2024-06-24 11:00 UTC [Leadership Update] [eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq](https://www.quantisnow.com/insight/effector-therapeutics-announces-it-will-wind-down-operations-as-it-5572215)
- 2024-06-14 20:01 UTC [SEC Form 8-K] [eFFECTOR Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/effector-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-5558891)
- 2024-06-13 22:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Loewy Caroline M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-loewy-caroline-m-5557311)
- 2024-06-13 22:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Klencke Barbara](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-klencke-barbara-5557303)
- 2024-06-13 22:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Ehrlich Christopher B](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ehrlich-christopher-b-5557279)
- 2024-06-13 22:23 UTC [SEC Form 4] [SEC Form 4 filed by Director Harrington-Smith Kristen](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-harrington-smith-kristen-5557277)
- 2024-06-13 22:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Gallagher Brian M. Jr.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gallagher-brian-m-jr-5557273)
- 2024-06-13 22:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Bhatt Elizabeth](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bhatt-elizabeth-5557268)
- 2024-05-28 12:07 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-pre-market-session-5518770)
- 2024-05-20 12:39 UTC [Market Chatter] [eFFECTOR Therapeutics And Dana-Farber Cancer Institute To Collaborate On Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin As Combination Treatment In ER+ Endometrial Cancer And In Low Grade Serous Ovarian Cancer](https://www.quantisnow.com/insight/effector-therapeutics-and-dana-farber-cancer-institute-to-collaborate-on-investigator-sponsored-5502963)
- 2024-05-20 12:36 UTC [SEC Form 8-K] [SEC Form 8-K filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-effector-therapeutics-inc-5502944)
- 2024-05-20 12:30 UTC [eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer](https://www.quantisnow.com/insight/effector-therapeutics-to-collaborate-with-the-dana-farber-cancer-institute-on-5502893)
- 2024-05-17 21:07 UTC [SEC Form 424B3] [SEC Form 424B3 filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-effector-therapeutics-inc-5501481)
- 2024-05-17 21:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-effector-therapeutics-inc-5501393)
- 2024-05-17 20:00 UTC [SEC Form 4] [Byrnes Michael was granted 1,387 shares, increasing direct ownership by 80% to 3,117 units (SEC Form 4)](https://www.quantisnow.com/insight/byrnes-michael-was-granted-1387-shares-increasing-direct-ownership-by-5500138)
- 2024-05-17 20:00 UTC [SEC Form 4] [Worland Stephen T was granted 1,806 shares, increasing direct ownership by 17% to 12,494 units (SEC Form 4)](https://www.quantisnow.com/insight/worland-stephen-t-was-granted-1806-shares-increasing-direct-ownership-5500134)
- 2024-05-13 20:05 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by eFFECTOR Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-effector-therapeutics-inc-amendment-5485213)
- 2024-05-09 21:11 UTC [SEC Form 424B5] [SEC Form 424B5 filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-effector-therapeutics-inc-5478906)
- 2024-05-09 20:51 UTC [SEC Form 424B3] [SEC Form 424B3 filed by eFFECTOR Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-effector-therapeutics-inc-5478619)
- 2024-05-09 20:51 UTC [Market Chatter] [eFFECTOR Therapeutics Q1 2024 GAAP EPS $(2.16) Beats $(2.17) Estimate; Reports Cash Runway Into Q1 Of 2025](https://www.quantisnow.com/insight/effector-therapeutics-q1-2024-gaap-eps-216-beats-217-estimate-5478614)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EFTR
- Earnings history: https://www.quantisnow.com/earnings/EFTR
- Dividend history: https://www.quantisnow.com/dividends/EFTR
- Insider transactions: https://www.quantisnow.com/insiders/EFTR
- Options chain: https://www.quantisnow.com/options/EFTR
- SEC 8-K filings only: https://www.quantisnow.com/company/EFTR/8-k
- RSS and alerts for EFTR: https://www.quantisnow.com/docs/rss-feeds.md
